Sector consensus Charles River Laboratories International, Inc.
Stocks
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
NYSE
04:00:02 2026-08-20 pm EDT
|
5-day change | 1st Jan Change | ||
| 291.45 USD | +0.50% |
|
+3.62% | +46.10% |
| Aug. 20 | Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing | MT |
| Aug. 20 | Charles River, Medigen Partner on Multivalent Enterovirus Vaccine | MT |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | 281 | -3.59% | 14 | ||||||
| 681.13 | +16.27% | 23 | ||||||
| 223.24 | +5.43% | 21 | ||||||
| 433.02 | +14.9% | 27 | ||||||
| 275.17 | +10.38% | 18 | ||||||
| 266,031.64 | +37.06% | 23 | ||||||
| 268.36 | +20.5% | 19 | ||||||
| 581.83 | -4.35% | 12 | ||||||
| 72.53 | -0.4% | 14 | ||||||
| 185.56 | +6.48% | 16 | ||||||
| 38.15 | -21.26% | 11 | ||||||
| 70.73 | -2.15% | 11 | ||||||
| 62.64 | +2.27% | 14 | ||||||
| 638.68 | +75.18% | 19 | ||||||
| 130.91 | +2.83% | 22 | ||||||
| 138.97 | +34.53% | 6 | ||||||
| 134.85 | +0.07% | 11 | ||||||
| 88 | +49.76% | 22 | ||||||
| 170.38 | +13.07% | 13 | ||||||
| 47.88 | +6.48% | 16 | ||||||
| Average | 13,527.73 | +13.17% | 17 | ||||||
| Weighted average by Cap. | 21,817.91 | +13.19% | 19 |
Select your edition
All financial news and data tailored to specific country editions
